Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1465-542X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer ; volume:21 ; number:1 ; day:13 ; month:6 ; year:2019 ; pages:1-3 ; date:12.2019
Breast cancer research ; 21, Heft 1 (13.6.2019), 1-3, 12.2019

Creator: Rimm, David L.
Han, Gang
Taube, Janis M.
Yi, Eunhee S.
Bridge, Julia A.
Flieder, Douglas B.
Homer, Robert
Roden, Anja C.
Hirsch, Fred R.
Wistuba, Ignacio I.
Pusztai, Lajos

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13058-019-1156-6

URN: urn:nbn:de:101:1-2019112523472298913880

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Rimm, David L.
Han, Gang
Taube, Janis M.
Yi, Eunhee S.
Bridge, Julia A.
Flieder, Douglas B.
Homer, Robert
Roden, Anja C.
Hirsch, Fred R.
Wistuba, Ignacio I.
Pusztai, Lajos
SpringerLink (Online service)

Other Objects (12)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Optimized PD-L1 scoring of gastric cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Clinical applications of PD-L1 bioassays for cancer immunotherapy

The intracellular signalosome of PD-L1 in cancer cells

Autophagy inhibition enhances PD-L1 expression in gastric cancer

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Optimized PD-L1 scoring of gastric cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Clinical applications of PD-L1 bioassays for cancer immunotherapy

The intracellular signalosome of PD-L1 in cancer cells

Autophagy inhibition enhances PD-L1 expression in gastric cancer

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Optimized PD-L1 scoring of gastric cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Clinical applications of PD-L1 bioassays for cancer immunotherapy

The intracellular signalosome of PD-L1 in cancer cells

Autophagy inhibition enhances PD-L1 expression in gastric cancer

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Optimized PD-L1 scoring of gastric cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Clinical applications of PD-L1 bioassays for cancer immunotherapy

The intracellular signalosome of PD-L1 in cancer cells

Autophagy inhibition enhances PD-L1 expression in gastric cancer

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Optimized PD-L1 scoring of gastric cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Clinical applications of PD-L1 bioassays for cancer immunotherapy

The intracellular signalosome of PD-L1 in cancer cells

Autophagy inhibition enhances PD-L1 expression in gastric cancer

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Optimized PD-L1 scoring of gastric cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-L1 degradation pathway and immunotherapy for cancer

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Clinical applications of PD-L1 bioassays for cancer immunotherapy

The intracellular signalosome of PD-L1 in cancer cells

Autophagy inhibition enhances PD-L1 expression in gastric cancer

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy

Related objects

Reset password